Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-03-22
2005-03-22
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
06869941
ABSTRACT:
A pharmaceutical dosage unit comprising drospirenone and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate for use in hormone replacement therapy is disclosed. This, combination therapy may comprise continuous or discontinuous administration of drospirenone and/or the estrogen sulphamate, such as weekly administration of both agents or weekly administration of the estrogen sulphamate and daily administration of the drospirenone.
REFERENCES:
patent: 3942641 (1976-03-01), Segre
patent: 4129564 (1978-12-01), Wiechert et al.
patent: 5827843 (1998-10-01), Koninckx
patent: RE36247 (1999-07-01), Plunkett et al.
patent: 6569844 (2003-05-01), Schwarz et al.
patent: RE38253 (2003-09-01), Spona et al.
patent: 20020132801 (2002-09-01), Heil et al.
patent: 44 29 398 (1996-02-01), None
patent: WO 9305064 (1993-03-01), None
patent: WO 9507081 (1995-03-01), None
patent: WO 9806738 (1998-02-01), None
patent: WO 9824801 (1998-06-01), None
patent: WO 9827929 (1998-07-01), None
patent: WO 0006175 (2000-02-01), None
patent: WO 0112801 (2001-02-01), None
patent: WO 0152857 (2001-07-01), None
Norman et al., “Drospirenone”, Drugs of the Future, 25(12), 1247-1256, 2000.*
Krattenmacher, “Drospirenone: pharmacology and pharmacokinetics of a unique progestogen”, Contraception, 62, 29-38, 2000.*
English language Abstract of WO 00/06175, 2000.*
English language Abstract for WO/00/06175, 2000.
English language Abstract for WO/98/27929, 1998.
English language Abstract for DE 3022337, 1980.
Oettel, et al., “Trends and perspectives of drug development for horomone replacement in women and men,”Abstracts, S-14, p. 254, 2000.
Norman et al., “Drospirenone,”Drugs of the Future, 2000, 25(12): 1247-1256.
Krattenmacher, “Drospirenone: pharmacology and pharmakinetics of a unique progestogen,”Contraception, 62 (2000), XP-000993492, pp. 29-38.
Casper et al., “Estrogen and interrupted progestin: A new concept for menopausal hormone replacement therapy,”Am. J. Obstet. Gynecol., vol. 168, No. 4, pp. 1188-1196, 1993.
Badio Barbara P.
Millen White Zelano & Branigan P.C.
Schering AG
LandOfFree
Combination of drospirenone and an estrogen sulphamate for HRT does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of drospirenone and an estrogen sulphamate for HRT, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of drospirenone and an estrogen sulphamate for HRT will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3404750